Procter & Gamble Health Limited has filed its quarterly compliance certificate with stock exchanges, confirming adherence to regulatory requirements for the quarter ended March 31, 2026. The submission was made on April 6, 2026, addressing obligations under SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Confirmation

The company submitted certificates to both BSE Limited and National Stock Exchange of India Limited, confirming compliance with Regulation 74(5) of SEBI regulations. Company Secretary Zeal Rupani signed the compliance documents, which were digitally authenticated on April 6, 2026.

Registrar Confirmation

Kfin Technologies Limited, serving as the company's Registrar and Transfer Agent, provided written confirmation of compliance. The registrar certified that details of securities dematerialized and rematerialized during the quarter were furnished to all stock exchanges where the company's shares are listed within prescribed timelines.

Ganesh Chandra Patro, Deputy Vice President at Kfin Technologies Limited, signed separate certificates addressed to both Central Depository Services (India) Limited and National Securities Depository Limited on April 1, 2026.

Stock Exchange Submissions

The compliance certificates were submitted to major Indian stock exchanges where Procter & Gamble Health Limited shares are traded. The filings ensure transparency in share dematerialization processes and maintain regulatory compliance standards.

This quarterly filing represents standard regulatory practice for listed companies, ensuring proper documentation and transparency in share transfer and dematerialization activities. The timely submission demonstrates the company's commitment to maintaining regulatory compliance and transparent reporting practices.

Procter & Gamble Health Limited has announced that its Board of Directors will convene on May 26, 2026, to review the company's audited financial statements for the financial year ended March 31, 2026, and consider recommendations for final dividend distribution to shareholders.

Board Meeting Details

The healthcare company formally notified the stock exchanges about the upcoming board meeting through a regulatory filing dated March 27, 2026. The meeting has been scheduled in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Agenda Items

The board meeting will address two primary matters of significant importance to shareholders and stakeholders. The directors will deliberate on the audited financial statements for the financial year ended March 31, 2026, providing a comprehensive review of the company's financial performance during this period. Additionally, the board will evaluate and potentially recommend a final dividend distribution, subject to their assessment of the company's financial position and future requirements.

Regulatory Communication

The company has fulfilled its disclosure obligations by informing both major stock exchanges about the scheduled board meeting. The communication was sent to BSE Limited, where the company trades under scrip code 500126, and to the National Stock Exchange of India Limited, where it is listed under the symbol PGHL.

Company Leadership

The regulatory filing was signed by Zeal Rupani, who serves as the Company Secretary of Procter & Gamble Health Limited. The digital signature was authenticated on March 27, 2026, ensuring proper documentation and compliance with regulatory requirements for corporate communications.